收费全文 | 23894篇 |
免费 | 1870篇 |
国内免费 | 38篇 |
耳鼻咽喉 | 276篇 |
儿科学 | 763篇 |
妇产科学 | 484篇 |
基础医学 | 3238篇 |
口腔科学 | 364篇 |
临床医学 | 2897篇 |
内科学 | 4782篇 |
皮肤病学 | 413篇 |
神经病学 | 2305篇 |
特种医学 | 651篇 |
外国民族医学 | 2篇 |
外科学 | 2892篇 |
综合类 | 249篇 |
一般理论 | 23篇 |
预防医学 | 2770篇 |
眼科学 | 502篇 |
药学 | 1579篇 |
中国医学 | 32篇 |
肿瘤学 | 1580篇 |
2023年 | 211篇 |
2022年 | 369篇 |
2021年 | 845篇 |
2020年 | 460篇 |
2019年 | 722篇 |
2018年 | 796篇 |
2017年 | 606篇 |
2016年 | 626篇 |
2015年 | 667篇 |
2014年 | 981篇 |
2013年 | 1239篇 |
2012年 | 1933篇 |
2011年 | 1919篇 |
2010年 | 984篇 |
2009年 | 849篇 |
2008年 | 1475篇 |
2007年 | 1377篇 |
2006年 | 1347篇 |
2005年 | 1305篇 |
2004年 | 1309篇 |
2003年 | 1127篇 |
2002年 | 1061篇 |
2001年 | 242篇 |
2000年 | 192篇 |
1999年 | 249篇 |
1998年 | 212篇 |
1997年 | 175篇 |
1996年 | 176篇 |
1995年 | 145篇 |
1994年 | 128篇 |
1993年 | 101篇 |
1992年 | 119篇 |
1991年 | 136篇 |
1990年 | 133篇 |
1989年 | 120篇 |
1988年 | 112篇 |
1987年 | 109篇 |
1986年 | 108篇 |
1985年 | 106篇 |
1984年 | 87篇 |
1983年 | 67篇 |
1982年 | 55篇 |
1981年 | 61篇 |
1980年 | 61篇 |
1979年 | 59篇 |
1978年 | 56篇 |
1977年 | 50篇 |
1976年 | 56篇 |
1975年 | 56篇 |
1972年 | 48篇 |
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献
Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献